Dr. John Kelvin Lalusis - Medical Oncologist Lung Cancer Specialist

Dr. John Kelvin Lalusis - Medical Oncologist Lung Cancer Specialist Luke's QC & BGC · Lung Center of the Philippines · Bataan He also treats head and neck, urologic, breast, and other adult cancers. Clinics: St.

Thoracic Oncologist & Lung Cancer Specialist | Medical Oncologist fellowship-trained at National Cancer Centre Singapore, with training at Toulouse University Cancer Institute, France | St. Dr. John Kelvin Lalusis is a Thoracic Oncologist and Lung Cancer Specialist in the Philippines — a board-certified Medical Oncologist with subspecialty fellowship training in Thoracic Oncology and Phase I Clini

cal Trials at the National Cancer Centre Singapore. He specializes in lung cancer and other chest (thoracic) cancers — including NSCLC, small cell lung cancer, mesothelioma, and thymic tumors — at all stages, offering targeted therapy, immunotherapy, chemotherapy, and clinical trial access guided by biomarker testing. Patients commonly consult him for a new diagnosis, a lung nodule or mass, a second opinion, or advanced-stage disease. Luke's Medical Center (Quezon City & Global City–BGC), Lung Center of the Philippines, and weekend clinics at Bataan St. Joseph Hospital and Medical Center (Balanga City, Bataan).

📅 Book a consultation: https://seriousmd.com/doc/john-kelvin-lalusis

Grateful to share that our team's work at the National Cancer Centre Singapore, "Real World Impact of Comprehensive Mole...
13/06/2026

Grateful to share that our team's work at the National Cancer Centre Singapore, "Real World Impact of Comprehensive Molecular Profiling on Treatment Selection in Patients Discussed in the IMPACT-SG Molecular Tumour Board," was recognized with a Best Poster award at ESMO TAT 2026 in Hong Kong.

A huge amount of credit goes to our Clinical Research Coordinator, Sharmaine, whose hard work and dedication resulted in a wonderful presentation.

In our retrospective analysis of 150 patients, we found that 65% received a molecularly matched recommendation, with 53% of those directed toward clinical trials. It is encouraging to see how comprehensive molecular profiling and multidisciplinary MTB reviews can help connect patients with targeted therapies and clinical trials.

It is truly a privilege to learn from and collaborate with Dr. Daniel Tan and this entire dedicated group.

07/06/2026

𝗢𝗻 𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗮𝗻𝗰𝗲𝗿 𝗦𝘂𝗿𝘃𝗶𝘃𝗼𝗿𝘀 𝗗𝗮𝘆, we celebrate more than victories—we celebrate the relentless spirit that keeps moving forward. Every finish line crossed is a testament that resilience outshines fear, that perseverance outlasts pain, and that hope, fueled by love and community, carries us beyond what once seemed possible.

To the survivors: your courage lights the way for others still walking the path. To families and caregivers: your unwavering support makes these triumphs possible. And to everyone listening: if you’re facing a challenge today, remember that the brave road to the finish line begins with choosing not to quit. The finish line you reach tomorrow is a promise you can keep today.


31/05/2026

📢 New Progress in EGFR+ Lung Cancer Research

Recent interim results from the Phase 2 ESAONA trial show a promising new option for patients with EGFR-mutated lung cancer and brain metastases.

The trial compared a new targeted drug, Asandeutertinib, against the current standard treatment (osimertinib):

Higher Response Rate:
Asandeutertinib shrank brain tumors in 95.5% of patients, compared to 79.6% with the standard treatment.

Longer Cancer Control:
The new drug kept brain tumors stable significantly longer. The average time before progression has not yet been reached, compared to 17.51 months with the standard therapy.

Conclusion:
While more data is needed, it shows strong potential as a future first-line treatment option.

We continue to monitor these medical advancements to ensure our patients receive the most current, evidence-based care.

🔬 Full study details here:

https://www.asco.org/abstracts-presentations/259625

https://dailynews.ascopubs.org/do/asandeutertinib-improves-intracranial-orr-pfs-vs-osimertinib-nsclc-brain-metastases

Address

St. Luke's Medical Center, 279 E Rodriguez Sr. Avenue
Quezon City
1112

Website

Alerts

Be the first to know and let us send you an email when Dr. John Kelvin Lalusis - Medical Oncologist Lung Cancer Specialist posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category